Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.01) EPS for the quarter, Zacks reports.
Guided Therapeutics Price Performance
GTHP stock traded down $0.04 during mid-day trading on Friday, reaching $0.25. The company had a trading volume of 2,230 shares, compared to its average volume of 16,468. The company has a market capitalization of $24.13 million, a PE ratio of -6.25 and a beta of 0.71. The firm has a 50 day moving average of $0.26 and a 200 day moving average of $0.27. Guided Therapeutics has a 12 month low of $0.15 and a 12 month high of $0.54.
Guided Therapeutics Company Profile
Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.
The company secured 510(k) clearance from the U.S.
Featured Stories
- Five stocks we like better than Guided Therapeutics
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
